CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapies for infectious and inflammatory diseases, with a focus on products like DefenCath® for bloodstream infections. The company actively advances its pipeline through clinical trials, regulatory submissions, strategic initiatives, and partnerships, aiming to address critical unmet medical needs and reduce health disparities.
Industries
Nr. of Employees
small (1-50)
CorMedix
300 Connell Drive, 4th Floor, Suite 4200, Berkeley Heights, NJ 07922
Patents
Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms
US-12302902-B2
View DetailsTaurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US-12053478-B2
View DetailsMethods and pharmaceutical compositions for treating candida auris in blood
US-12016865-B2
View DetailsAntimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same
US-10517984-B2
View Details
Antimicrobial compositions, including antimicrobial hydrogels, effective against mature biofilms
US-12302902-B2
View DetailsTaurultam, taurinamide and methylene glycol treatment for MYC—expressing tumors in mammalian bodies
US-12053478-B2
View DetailsMethods and pharmaceutical compositions for treating candida auris in blood
US-12016865-B2
View DetailsAntimicrobial wound closure materials, including antimicrobial sutures, and method for closing a wound using the same
US-10517984-B2
View DetailsProducts
Catheter-lock solution (antimicrobial + anticoagulant)
A catheter-lock formulation combining an antimicrobial small-molecule chemistry with an anticoagulant to reduce catheter-related bloodstream infections in patients with central venous catheters.
Catheter-lock solution (antimicrobial + anticoagulant)
A catheter-lock formulation combining an antimicrobial small-molecule chemistry with an anticoagulant to reduce catheter-related bloodstream infections in patients with central venous catheters.
Services
Collaborative development, in-licensing and co-development of antimicrobial therapeutics and device candidates, including sharing preclinical data and development expertise.
Formation of commercial agreements with healthcare providers and operators, and execution of reimbursement and distribution strategies to enable inpatient and outpatient availability.
Collaborative development, in-licensing and co-development of antimicrobial therapeutics and device candidates, including sharing preclinical data and development expertise.
Formation of commercial agreements with healthcare providers and operators, and execution of reimbursement and distribution strategies to enable inpatient and outpatient availability.
Expertise Areas
- Phase 3 clinical trial management
- Regulatory strategy and NDA/MAA submission management
- CMC development and GMP manufacturing scale-up
- Antimicrobial therapeutics and prevention of device-associated infections
Key Technologies
- Catheter-lock formulation (antimicrobial + anticoagulant)
- Small-molecule antimicrobial chemistry
- Antimicrobial device coating technologies
- Topical hydrogel formulation
News & Updates
Learn about the latest progress with their product and pipeline.
CorMedix announced FDA approval of DefenCath® to reduce catheter-related bloodstream infections in adult hemodialysis patients.
Received FDA approval for DefenCath® to reduce bloodstream infections in dialysis patients.
Learn about the latest progress with their product and pipeline.
CorMedix announced FDA approval of DefenCath® to reduce catheter-related bloodstream infections in adult hemodialysis patients.
Received FDA approval for DefenCath® to reduce bloodstream infections in dialysis patients.